CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma - PubMed
5 days ago
- #CAR T-cell therapy
- #clinical research
- #marginal zone lymphoma
- CAR T-cell therapy is being studied for patients with relapsed or refractory marginal zone lymphoma.
- The study received support from the National Natural Science Foundation of China, Tianjin Natural Science Foundation, and Tianjin Key Medical Discipline Construction Project.
- Authors SZ, HZ, and XW declare no competing interests.